Streetbeat News

Earnings

ALLO

Allogene Therapeutics (NASDAQ:ALLO) is expected to report a Q4 earnings per share (EPS) of $-0.45 on March 14, 2024. Historical data shows the company has previously beaten EPS estimates, leading to significant share price movements. Shares are currently trading at $4.9, down 10.44% over the last year. Investors will be closely watching for earnings performance and future guidance.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 6:01 pm

EQT

ETRN

Mizuho Securities analyst Nitin Kumar downgraded EQT Corporation (NYSE:EQT) to Neutral from Buy, reducing the price target to $39 from $46, citing FY23 reserves, 2024 guidance, and the proposed merger with Equitrans Midstream Corporation (NYSE:ETRN). The merger, an all-stock transaction, aims to create a company with an enterprise value over $35 billion. EQT's Q4 revenue and adjusted EPS fell short of expectations, and FY24 guidance suggests modest dilution to NAV due to higher operating expenses. Kumar expects EQT to focus on debt reduction and asset integration, leading to potential cash returns, with a 2025 FCF breakeven of $2.20/mcf for the combined company.

Portfolio Pulse from Lekha Gupta

March 13, 2024 | 6:01 pm

RMBS

Analyst ratings for Rambus (NASDAQ:RMBS) show a positive trend, with recent evaluations varying from bullish to bearish. The average 12-month price target has been raised to $85.00, indicating a 6.25% increase from the previous target of $80.00. Rambus, a semiconductor solutions provider, has shown exceptional financial performance with a high net margin of 47.9% and strong ROE and ROA figures. However, its market capitalization and revenue growth lag behind industry peers.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 6:01 pm

RDW

Redwire (NYSE:RDW) is expected to report a Q4 earnings per share (EPS) of $-0.12 on March 14, 2024. Analysts and investors will be looking for an earnings beat and positive guidance for the next quarter. Historical performance shows mixed results with the last quarter missing EPS estimates by $0.00, leading to a 7.37% drop in share price. Over the last 52 weeks, RDW shares have increased by 2.34%, trading at $3.17 as of March 12.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 6:01 pm

FTHM

Fathom Holdings (NASDAQ:FTHM) is scheduled to release its quarterly earnings report on March 14, 2024, with an expected EPS of $-0.32. Historical performance shows mixed reactions to past earnings, with a notable 2.07% drop after last quarter's miss. Shares have declined 45.95% over the last year, indicating potential investor concern ahead of the announcement.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 6:01 pm

BRLT

Brilliant Earth Group (NASDAQ:BRLT) is scheduled to release its quarterly earnings report on March 14, 2024, with an estimated EPS of $0.01. Analysts and investors will be closely watching for not only an earnings beat but also positive guidance for future growth. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's beat followed by a 13.7% drop. Currently, BRLT shares are trading at $2.71, marking a 29.82% decline over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 6:01 pm

URGN

UroGen Pharma (NASDAQ:URGN) is scheduled to release its quarterly earnings report on March 14, 2024, with analysts expecting an EPS of $-0.68. The company's past performance shows a mixed reaction to earnings reports, with the stock price fluctuating based on actual EPS versus estimates and subsequent guidance. Over the last year, URGN shares have increased by 85.85%, indicating a positive outlook from long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 6:01 pm

AGEN

Agenus (NASDAQ:AGEN) is scheduled to release its quarterly earnings report on March 14, 2024, with analysts expecting an EPS of $-0.05. The company's past earnings performance shows a trend of beating EPS estimates, leading to positive stock price movements the following day. However, Agenus shares have declined by 62.46% over the last 52 weeks, indicating long-term shareholder dissatisfaction. Investors will be closely watching the upcoming earnings report, especially the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 6:01 pm

CISO

CISO Global shares are trading higher following the announcement of their preliminary FY23 guidance, indicating positive future performance.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 5:58 pm

ATER

Aterian shares are trading lower following the announcement of their Q4 financial results, which were below expectations. Additionally, the company's Q1 net revenue guidance was issued below estimates, further impacting the stock's performance.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 5:56 pm